| abstract |
The present invention relates to the use of the human or animal MCM9 gene, or parts of said gene, or transcripts thereof, or antisense nucleic acids able to hybridize with part of said gene or transcripts, or silencing RNA derived from parts of said transcripts and able to repress said MCM9 gene, or proteins or peptidic fragments translated from said transcripts, or antibodies directed against said proteins or peptidic fragments, for the preparation of a pharmaceutical composition for the treatment of a human or animal pathology linked to a dysfunction of the expression of the MCM9 gene, or of human or animal cancers. |